



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION



Bepotastine (besylate)

Item No. 23721

CAS Registry No.: 190786-44-8

Formal Name: 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy]-1-piperidinebutanoic acid, monobenzenesulfonate

Synonyms: Bepotastine besilate, TAU-284

MF: C₂₁H₂₅CIN₂O₃ • C₆H₆O₃S


FW: 547.1

Purity: ≥95%

Supplied as: A solid

Storage: 4°C

Stability: ≥1 year



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Bepotastine (besylate) is supplied as a solid. A stock solution may be made by dissolving the bepotastine (besylate) in the solvent of choice. Bepotastine (besylate) is soluble in organic solvents such as methanol and DMSO, which should be purged with an inert gas.

Description

Bepotastine is an antagonist of the histamine H₁ receptor that is selective over H₃, α₁-, α₂-, and β-adrenergic, dopamine D_{2long}, serotonin 5-HT₂, muscarinic acetylcholine, and benzodiazepine receptors.¹ It reduces dye leakage from the nasal passages of rats acutely sensitized to an antigen (ED₅₀ = 0.03 mg/kg) and inhibits histamine-induced bronchoconstriction in the anesthetized dog (ED₅₀ = 3.2 µg/kg).^{2,3} Bepotastine prevents conjunctival vascular hyperpermeability in a guinea pig model of conjunctivitis in a dose-dependent manner.⁴ Formulations containing bepotastine have been used in the treatment of itching associated with allergic conjunctivitis.

References

1. Kato, M., Nishida, A., Aga, Y., et al. Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate. *Arzneimittelforschung*. **47**(10), 1116-1124 (1997).
2. Murata, T., Matsumoto, Y., Suzuki, T., et al. Effect of betotastine besilate (TAU-284), a novel anti-allergic agent, on experimental allergic rhinitis. *Arerugi* **46**(7), 576-584 (1997).
3. Matsubara, S., Ono, C., Yamazaki, N., et al. Inhibitory effects of bepotastine, a novel anti-allergic drug on histamine-induced bronchoconstriction in anesthetized dogs. *Yakuri to Chiryo* **25**(4), 895-900 (1997).
4. Kida, T., Fuji, A., Sakai, O., et al. Bepotastine besilate, a highly selective histamine H₁ receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in *in vitro* and *in vivo* experimental allergic conjunctivitis models. *Exp. Eye Res.* **91**(1), 85-91 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.